RT Journal Article
T1 Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics.
A1 Jimenez-Luna, Cristina
A1 Martin-Blazquez, Ariadna
A1 Dieguez-Castillo, Carmelo
A1 Diaz, Caridad
A1 Martin-Ruiz, Jose Luis
A1 Genilloud, Olga
A1 Vicente, Francisca
A1 Del Palacio, Jose Perez
A1 Prados, Jose
A1 Caba, Octavio
K1 biomarker
K1 chronic pancreatitis
K1 diagnosis
K1 metabolomics
K1 pancreatogenic diabetes mellitus
K1 type 2 diabetes mellitus
K1 untargeted LC-HRMS
AB Pancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find differential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five differential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the differential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases.
SN 2218-1989
YR 2020
FD 2020-10-22
LK https://hdl.handle.net/10668/25247
UL https://hdl.handle.net/10668/25247
LA en
DS RISalud
RD Apr 8, 2025